Quaternity method for integrated screening, separation, extraction optimization, and bioactivity evaluation of acetylcholinesterase inhibitors from Sophora flavescens Aiton

Abstract

AbstractIntroductionSophora flavescens Aiton (Fabaceae), a ubiquitous plant species in Asia, contains a wide range of pharmacologically active compounds, such as flavonoids, with potential anti‐Alzheimer's disease (anti‐AD) effects.ObjectivesThe objective of the study is to develop a quaternity method for the screening, isolation, extraction optimization, and activity evaluation of acetylcholinesterase (AChE)‐inhibiting compounds from S. flavescens to realize high‐throughput screening of active substances in traditional Chinese medicine and to provide experimental data for the development of anti‐AD drugs.MethodsWith AChE as the target molecule, affinity ultrafiltration and liquid chromatography‐mass spectrometry were applied to screen for potential inhibitors of the enzyme in S. flavescens. Orthogonal array experiments combined with the multi‐objective Non‐Dominated Sorting Genetic Algorithm III was used for the first time to optimize the process for extracting the active substances. Enzyme inhibition kinetics and molecular docking studies were performed to verify the potential anti‐AD effects of the active compounds.ResultsFive AChE‐inhibiting compounds were identified: kushenol I, kurarinone, sophoraflavanone G, isokurarinone, and kushenol E. These were successfully separated at purities of 72.88%, 98.55%, 96.86%, 96.74%, and 95.84%, respectively, using the n‐hexane/ethyl acetate/methanol/water (4.0/5.0/4.0/5.0, v/v/v/v), n‐hexane/ethyl acetate/methanol/water (5.0/5.0/6.0/4.0, v/v/v/v), and n‐hexane/ethyl acetate/methanol/water (4.9/5.1/5.7/4.3, v/v/v/v) mobile phase systems. Enzyme inhibition kinetics revealed that kushenol E had the best inhibitory effect.ConclusionThis study elucidates the mechanism of action of five active AChE inhibitors in S. flavescens and provides a theoretical basis for the screening and development of anti‐AD and other therapeutic drugs.